Search
Cardiolipin Biosynthesis CL(10:0/i-15:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0181638MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-16:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0181870MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-19:0/i-20:0/i-20:0)
smpdb.ca/view/SMP0182268MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Cardiolipin Biosynthesis CL(10:0/i-20:0/i-20:0/i-24:0)
smpdb.ca/view/SMP0182337MetabolicCardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.
Acylcarnitine (10Z)-7-Hydroxyhexadecenoylcarnitine
smpdb.ca/view/SMP0124266Metabolic(10Z)-7-Hydroxyhexadecenoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (10Z)-7-hydroxyhexadecenoyl-CoA reacts with L-carnitine to form (10Z)-7-hydroxyhexadecenoylcarnitine.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreAcylcarnitine (10Z)-12-Hydroxyhexadecenoylcarnitine
smpdb.ca/view/SMP0124269Metabolic(10Z)-12-Hydroxyhexadecenoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (10Z)-12-hydroxyhexadecenoyl-CoA reacts with L-carnitine to form (10Z)-12-hydroxyhexadecenoylcarnitine.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreAmbenonium
go.drugbank.com/drugs/DB01122ApprovedWithdrawnIt is used in the management of myasthenia gravis.
Etirinotecan pegol
go.drugbank.com/drugs/DB14951InvestigationalEtirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).
Toll-like receptor 9
go.drugbank.com/drugs/DB15320InvestigationalToll-like receptor 9 is under investigation in clinical trial NCT03007732 (Pembrolizumab in Combination With Intratumoral SD-101 Therapy).
Bezlotoxumab
go.drugbank.com/drugs/DB13140ApprovedBezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce th...